63190-58-9

Usage

Uses

Used in Pharmaceutical Industry:
2,3,6-trimethylquinazolin-4(3H)-one is used as a potential anti-cancer agent for its pharmacological properties. It has been studied for its potential to inhibit the growth and progression of various types of cancer, making it a promising candidate for cancer treatment.
Used in Enzyme Inhibition:
2,3,6-trimethylquinazolin-4(3H)-one is used as an inhibitor of various enzymes, which can be beneficial in the development of drugs targeting specific enzyme-related diseases or conditions. Its ability to inhibit enzymes makes it a valuable compound for further research and potential applications in the treatment of various diseases.
Used in Medicinal Chemistry Research:
2,3,6-trimethylquinazolin-4(3H)-one is used as a target for further research in the field of medicinal chemistry. Its unique structure and promising biological activities make it an interesting compound for the development of new drugs and therapeutic agents.
Used in Drug Development:
2,3,6-trimethylquinazolin-4(3H)-one is used in drug development for its potential to be formulated into new pharmaceuticals. Its diverse biological activities and potential as an anti-cancer agent and enzyme inhibitor make it a valuable compound for the creation of novel therapeutic agents.

Upstream product

• 62175-49-9 2-methyl-6-methyl-4H-3,1-benzoxazin-4-one 
• 593-51-1 methylamine hydrochloride 
• 74786-81-5 m-methyl-N-methylbenzamide 
• 1711-06-4 3-Methylbenzoyl chloride 
• 145746-76-5 N-Acetyl-5,N-dimethyl-2-nitro-benzamide 

Relevant academic research and scientific papers

Cp?CoIII-catalyzed formal [4+2] cycloaddition of benzamides to afford quinazolinone derivatives

A Cp?CoIII-catalyzed arene C-H bond amidation/annulation of benzamides was developed to afford quinazolinone derivatives in one-pot with high yields and broad substrate scope. This method could be applied to the synthesis of quinazolinone drugs and late-stage modification of natural products.

Analogues of 4-[(7-Bromo-2-methyl-4-oxo-3 H -quinazolin-6-yl)methylprop-2- ynylamino]- N -(3-pyridylmethyl)benzamide (CB-30865) as potent inhibitors of nicotinamide phosphoribosyltransferase (Nampt)

We have shown previously that the target of the potent cytotoxic agent 4-[(7-bromo-2-methyl-4-oxo-3H-quinazolin-6-yl)methyl-prop-2-ynylamino] -N-(3-pyridylmethyl)benzamide (CB38065, 1) is nicotinamide phosphoribosyltransferase (Nampt). With its cellular target known we sought to optimize the biochemical and cellular Nampt activity of 1 as well as its cytotoxicity. It was found that a 3-pyridylmethylamide substituent in the A region was critical to cellular Nampt activity and cytotoxicity, although other aromatic substitution did yield compounds with submicromolar enzymatic inhibition. Small unsaturated groups worked best in the D-region of the molecule, with 3,3-dimethylallyl providing optimal potency. The E region required a quinazolin-4-one or 1,2,3-benzotriazin-4-one group for activity, and many substituents were tolerated at C2 of the quinazolin-4-one. The best compounds showed subnanomolar inhibition of Nampt and low nanomolar cytotoxicity in cellular assays.

Transition-Metal Complex-Catalyzed Reductive N-Heterocyclization: Synthesis of 4(3H)-Quinazolinone Derivatives from N-(2-Nitrobenzoyl)amides

Several ruthenium and platinum complexes smoothly catalyze the reductive N-heterocyclization of N-(2-nitrobenzoyl)amides under carbon monoxide pressure to afford the corresponding 4(3H)-quinazolinone derivatives, including some quinazolinone alkaloids, in